Markets:

Overview

News

Currencies

International

Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

14.26 -1.14 (-7.40%)

Streaming Delayed Price Updated: 11:04 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 30, 2022

Gainers Adagio Therapeutics (NASDAQ:ADGI) shares increased by 52.2% to $5.86 during Wednesday's pre-market session. The company's market cap stands at $651.9 million.

Via Benzinga

Omeros's Return On Capital Employed Insights ↗

March 07, 2022

According to Benzinga Pro, during Q4, Omeros (NASDAQ:OMER) earned $280.62 million, a 1336.05% increase from the preceding quarter. Omeros also posted a total of $30.84 million in...

Via Benzinga

Omeros: Q4 Earnings Insights ↗

March 01, 2022

Omeros (NASDAQ:OMER) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros missed...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022

February 24, 2022

From Omeros Corporation

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗

January 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...

Via Benzinga

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA ↗

January 20, 2022

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated...

Via Benzinga

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

January 19, 2022

From Omeros Corporation

Via Business Wire

Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

December 23, 2021

From Omeros Corporation

Via Business Wire

Omeros Corporation (NASDAQ:OMER) Investor Notice: Investigation over Potential Wrongdoing ↗

December 14, 2021

San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Certain directors of Omeros Corporation are under investigation over potential breaches of fiduciary duties.

Via SBWire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 09, 2021

Gainers Applied DNA Sciences (NASDAQ:APDN...

Via Benzinga

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm

December 05, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 03, 2021

Gainers Lixte Biotech Holdings (NASDAQ:LIXT

Via Benzinga

Omeros Offloads Cataract Med Omidria To Rayner Surgical In Deal Valued Over $1B ↗

December 02, 2021

Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 02, 2021

Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market value of their outstanding shares is at $493.4 million...

Via Benzinga

Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion

December 02, 2021

From Omeros Corporation

Via Business Wire

76 Biggest Movers From Yesterday ↗

November 11, 2021

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares...

Via Benzinga

Topics Initial Public Offering

Omeros: Q3 Earnings Insights ↗

November 09, 2021

Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros...

Via Benzinga

Omeros Corporation Reports Third Quarter 2021 Financial Results

November 09, 2021

From Omeros Corporation

Via Business Wire

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Earnings Outlook For Omeros ↗

November 08, 2021

Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years ↗

November 05, 2021

Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA...

Via Benzinga

Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial

November 05, 2021

From Omeros Corporation

Via Business Wire

Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis

November 05, 2021

From Omeros Corporation

Via Business Wire

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021

November 04, 2021

From Omeros Corporation

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗

November 02, 2021

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...

Via Benzinga

3 Beaten-Down Biotech Stocks -- Can They Recover? ↗

October 31, 2021

Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.

Via The Motley Fool

NASDAQ:OMER Investor Notice: Investigation over Possible Securities Laws Violations by Omeros Corporation ↗

October 22, 2021

San Diego, CA -- (SBWIRE) -- 10/22/2021 -- An investigation was announced concerning potential securities laws violations by Omeros Corporation in connection with certain financial statements.

Via SBWire

10 Biggest Price Target Changes For Tuesday ↗

October 19, 2021

Goldman Sachs boosted Walmart Inc. (NYSE:WMT) price...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.